Special Issue "New Molecular Insights into Neurocutaneous Syndromes"
Deadline for manuscript submissions: closed (31 July 2022) | Viewed by 7895
Interests: new technologies and methods for molecular diagnosis; discovery of disease-severity-determining molecular factors; analysis of molecular pathway dysfunctions and cross-talking abnormalities associated with gene mutations; quest for possibilities of new molecular targeted drugs
Neurocutaneous syndrome is a category of genetic disease characterized by both skin and brain lesions with tumor formation, which comprises neurofibromatosis type 1 (NF1), tuberous sclerosis complex (TSC), Sturge–Weber syndrome (SWS), and various other disorders. In recent years, causative genes of these syndromes have been identified, and these molecules have been revealed to commonly regulate RAS/MAPK and PI3K/mTOR pathways, which are also shared with cancer. This has led to the emergence of a new concept based on which neurocutaneous syndromes have a common molecular basis as a framework, and clinical application of molecular targeted drugs such as mTOR inhibitors has been done. Genetic diagnosis of these syndromes is still difficult because mutation patterns are diverse, including deep intronic mutations, and a certain population of patients have mosaic mutations. SWS (GNAQ) and some rare RAS mutation syndromes are caused by specific gain-of-function mutations as somatic mosaicism. Syndromes caused by haploinsufficiency due to loss-of-function mutations such as NF1 and TSC are basically no genotype–phenotype correlations. However, the severity of individual patient varies even in a single family for some unknown reason. In this Special Issue, we will focus on new molecular insight of neurocutaneous syndromes, welcoming all those studies on more sophisticated genetic diagnosis, discovery of severity-determining factors, analysis of molecular pathway dysfunctions and cross-talking abnormalities associated with gene mutations, and quest for possibilities of new molecular targeted drugs.
Dr. Yo Niida
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Neurocutaneous syndromes
- Neurofibromatosis type 1
- Tuberous sclerosis complex
- Sturge–Weber syndrome
- Molecular diagnosis
- Mosaic mutation
- Deep intronic mutation
- Molecular basis of risk factors for disease severity
- RAS/MAPK pathway
- PI3K/mTOR pathway
- Dysregulation of signal transduction pathway caused by gene mutations
- Molecular targeted therapy